Qanatpharma is a clinical-stage biopharma company specializing in microvascular research and medicine.
Unlocking Microvascular Potential
QP develops new therapeutic strategies to address microvascular dysfunction, a common feature of many diseases that remain high unmet medical needs, like cognitive decline and hypertension.
QP's pipeline includes research in different vascular beds, transcriptomic/proteomic approaches, AI/machine-learning strategies, and a range of disease models to validate its targets and accelerate drug identification/design.
Our Phase 2 proof-of-concept trial will investigate a new use for a cystic fibrosis drug in the treatment of compromised cerebral blood flow in heart failure.
Blending academic rigour and industry expertise to advance microvascular medicine
QP's team is based in Canada, Germany, and Switzerland and partners with top scientific and clinical centres to integrate interdisciplinary ideas, technical approaches and methodologies in our work.
The term “microcirculation” describes an arrangement of highly specialized blood vessels, ultimately designed to enable the exchange processes that are vital to cell survival.
_
Resistance Arteries
At 10-250 microns in diameter, resistance arteries are main control points located just before the capillaries where the exchange processes occur, regulating organ blood flow and systemic blood pressure.
_
Myogenic Response
Under normal conditions, smooth muscle cells in the vessel wall actively adjust their level of constriction in response to the prevalent pressure level. This key microvascular mechanism, which keeps blood flow constant over a large range of pressures, is termed the “myogenic response” (MR).
_
Microvascular Dysfunction
Microvascular dysfunction (MD) is a primary driver of disease progression and negative clinical outcome. QP’s proprietary approaches focus on mechanism-based treatments that normalize MR to restore normal microvascular function.
.jpg)
